Dec. 4, 2017 Price forecast | 2 weeks: -0.46% | 1 month: -0.14% | 3 months: -0.73%


CRSP stock forecast

Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$.

In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. During that period the price should oscillate between -7.90% and +8.10%.

In the medium term (3months), CRSP's stock price should underperform the market by -0.73%. During that period the price should oscillate between -16.76% and +21.47%.


About CRISPR Therapeutics AG

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.

At the moment the company generates 2M USD in revenues.

On its last earning announcement, the company reported a loss of -3.75$ per share.

The book value per share is 5.62$

CRISPR Therapeutics AG website


Three months stock forecastDec. 4, 2017


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
2M - -180M - -185M -3.75 - - 50M 5.62 -117M -3M -121M